英医生发现应对乳腺癌速效药 2周癌细胞消失

2016-03-13 腾讯科学腾讯科学

据BBC报道，英国医生发现有两种药物对于乳腺癌治疗有着明显的效果，这意味着某些女性将不再需要进行化疗。这些药物在257位女性患者的身上进行了测试，主要针对的是十分之一女性乳腺癌患者中的一种特定弱点。专家声称这一发现可以说是定制癌症疗法的垫脚石。负责这项实验的医生们并未预料到会达到这样惊人的效果。他们过去一直在研究药物在确诊和手术进行期间如何对癌症产生作用。但是当医生们进行手术时，部分病人体内的癌症

据BBC报道，英国医生发现有两种药物对于乳腺癌治疗有着明显的效果，这意味着某些女性将不再需要进行化疗。这些药物在257位女性患者的身上进行了测试，主要针对的是十分之一女性乳腺癌患者中的一种特定弱点。

专家声称这一发现可以说是定制癌症疗法的垫脚石。负责这项实验的医生们并未预料到会达到这样惊人的效果。他们过去一直在研究药物在确诊和手术进行期间如何对癌症产生作用。但是当医生们进行手术时，部分病人体内的癌症迹象甚至已经消失。

伦敦癌症研究中心的Judith Bliss教授称：“我们对于这些发现感到十分惊奇，因为这项研究呈现的是一种短期疗效。似乎在某些病人体内出现了复杂的反应，这是一种非常令人着迷的治疗效果。”

研究中所使用的两种药物为拉帕替尼和曲妥单抗（也就是我们通常所说的赫赛汀），它们的治疗目标都是HER2，这种蛋白会促使某些女性患者乳腺癌的增长。赫赛汀会作用在癌细胞表面，而拉帕替尼渗透到细胞内部来使HER2蛋白失去功效。

在不到两个周的治疗时间里，11%的癌症患者体内的癌细胞完全消失，17%的患者体内肿瘤缩小到不到5毫米。目前治疗HER2蛋白阳性乳腺癌的手段就是手术，然后进行化疗和赫赛汀治疗。

但是Bliss教授认为这些发现可能意味着部分乳腺癌患者不再需要化疗。然而这仍然需要进行更多的研究，特别是HER2蛋白阳性乳腺癌的复发风险更高。Bliss教授称：“我们首先必须清楚，我们不能够增加其复发的风险。”

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (22)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的？继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的！, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
2016-03-23 jetleo

快进医保

151 0
[GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的？继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的！, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
2016-03-23 jetleo

HER2蛋白阳性乳腺癌的复发风险更高

187 0
[GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的？继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的！, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
2016-03-23 jetleo

意味着部分乳腺癌患者不再需要化疗

188 0
[GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的？继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的！, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
2016-03-19 1de833cem82(暂无匿称)

临床实验成功后意义重大

186 0
[GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的？继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的！, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
2016-03-16 任然

真的假的？继续关注

99 0
[GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的？继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的！, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
2016-03-16 numenboy

大多数人还是用不起的！

197 0
[GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的？继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的！, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
2016-03-15 yxch36

#癌细胞#

75 0
[GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的？继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的！, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
2016-03-14 忠诚向上

好好学习，继续研究

124 0
[GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的？继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的！, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
2016-03-14 忠诚向上

好好学习，继续研究

53 0
[GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的？继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的！, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
2016-03-14 忠诚向上

好好学习，继续研究

114 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

英医生发现应对乳腺癌速效药 2周癌细胞消失

相关资讯

科室

工具

服务